Argenica Therapeutics Ltd · ASX:AGN
Argenica Therapeutics — Investor Presentation (July 2023)
18 slides from Argenica Therapeutics's investor presentation, Jul 25, 2023
Slide 1: Investor Presentation
INVESTOR ARGENICA THERAPEUTICS PRESENTATION ASX: AGN BIOSHARES BIOTECH SUMMIT JULY 2023 1 www.argenica.com.au
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Argenica Therapeutics Limited and its related entities (the “Company”) and is not an offer document. It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company
Slide 3: Argenica Overview
ARGENICA OVERVIEW NOVEL UNTAPPED SUCCESSFUL BUILDING NEUROPROTECTIVE COMMERCIAL CLINICAL COMPANY TREATMENTS OPPORTUNITY PROGRESS VALUE ARGENICA THERAPEUTICS STROKE PHASE 2 URGENT & UNMET SECURED 90% SHARE PRICE CLINICAL NEED MANUFACTURING INCREASE FROM IPO2 SIS1 PHASE 2 NO MARKETED COMPLETED PROGRES
Slide 4: Key Company Metrics
KEY COMPANY METRICS $9.3M +$4M R&D REFUND EXPECTED CASH @ BANK1 NON-DILUTIVE GRANTS2 Q4 CY23 ARGENICA THERAPEUTICS 98.3M $36M FUNDED SHARES ON ISSUE MARKET CAP3 TO COMMENCE PHASE 2 1. Cash balance as @ 30 June 2023 2. ASX Announcement titled ‘Argenica Successfully Completes $4.0M Placement’ dated 2
Slide 5: Our Lead Drug Candidate: ARG-007
OUR LEAD DRUG CANDIDATE: ARG-007 CATIONIC POLY-ARGININE PEPTIDE ARGENICA THERAPEUTICS MULTIPLE MECHANISMS OF ACTION GRANTED PATENTS & STRONG IP SIGNIFICANT PRE-CLINICAL EFFICACY 25+ PUBLISHED PEER REVIEWED PAPERS PROVEN SAFE FOR HEALTHY HUMANS WORLD LEADING PARTNERS 5 www.argenica.com.au
Slide 6: Ischemic Stroke Example
ISCHEMIC STROKE EXAMPLE ARG-007 REDUCES BRAIN CELL DEATH ARGENICA THERAPEUTICS INITIAL INFARCTION SETS OFF A CASCADE OF CELL DEATH THAT WILL CONTINUE SPREADING FROM LOCATION Without protection 1.9 million brain cells die every minute ARG-007 slows this brain cell death Extends treatment window & pro
Slide 7: Multiple ARG-007 Mechanisms of Action in Stroke
MULTIPLE ARG-007 Represents where ARG-007 MECHANISMS significantly impacts activity OF ACTION IN STROKE ARGENICA THERAPEUTICS ARG-007 targets multiple pathways for effective stroke therapy: Reduces calcium influx Preserves mitochondrial membrane potential NMDA (NR2B) downregulation Reduces GFAP and
Slide 8: Animal Stroke Studies
ANIMAL STROKE STUDIES Date Animal Model Peptide(s) MCAO Type Induction Dosing (nmol/kg) Administration Assessment (post Analysed (post MCAO) MCAO) 2016 Sprague-Dawley rat R18; NA-1 Permanent Surgical 100, 300, 1000 60mins 24Hrs 2016 Sprague-Dawley rat R18; R12; R15 Permanent Surgical 1000 30mins 24H
Slide 9: More Effective Than Our Nearest Competitor
MORE EFFECTIVE THAN OUR NEAREST COMPETITOR Percentage reduction of brain tissue death after stroke 24 Hours after stroke 28 Days after stroke 100% INDUCED INDUCED 90% STROKE STROKE Reduction in brain cell death 80% can make a significant difference to patients’ ARGENICA THERAPEUTICS 70% outcome. It
Slide 10: The Ideal Stroke Therapeutic
THE IDEAL STROKE THERAPEUTIC PREVIOUS BARRIERS FOR WHAT SETS NEUROPROTECTIVE DRUGS ARG-007 APART Do not fit into current standard of care ARG-007 has multi-functional ARGENICA THERAPEUTICS mechanisms of action Past drugs focused on targeting singular Has shown significant efficacy in different mecha
Slide 11: The Stroke Opportunity
THE STROKE OPPORTUNITY ESTIMATED US$183 BILLION ARGENICA THERAPEUTICS TO TREAT STROKE BY 20301 ~550-600K ADMISSIONS FOR ACUTE ISCHEMIC STROKE IN THE U.S. PER YEAR2 ARG-007 PRICE PER-DOSE EXPECTED TO BE USD$8k – $10K - SIMILAR TO tPA3 1. Gorelick PB. “The global burden of stroke: persistent and disab
Slide 12: ARG-007 Clinical Milestones Achieved
ARG-007 CLINICAL MILESTONES ACHIEVED ARG-007 proved safe and well-tolerated in healthy human Phase 1 ARGENICA THERAPEUTICS Sterile Fill & Finish GMP manufacturing of ARG-007 initiated Stroke & Emergency Medicine experts to run Phase 2 trial Phase 2 trial site principal investigator neurologists enga
Slide 13: Phase 2 Clinical Trial in Stroke Overview and Timeline
PHASE 2 CLINICAL TRIAL IN STROKE Q3 Q4 Q1 Q2 OVERVIEW TIMELINE1 CY23 CY23 CY24 CY24 Up to 10 Australian hospitals Pre-IND FDA meeting Double-blinded, randomised, ARGENICA THERAPEUTICS Ethics approval2 placebo-controlled study Hospital site start-up ARG-007 will be given to patients that have suffere
Slide 14: Phase 2 Clinical Trial Team
PHASE 2 CLINICAL TRIAL TEAM Prof. Graeme Hankey A/Prof Tina Soulis National Coordinating Principal Investigator Alithia Life Sciences, Founder and Director As a neurologist-scientist, Professor Hankey has made an A/Prof Soulis has over 27 years of working in the healthcare outstanding lifetime contr
Slide 15: Pipeline of Additional Indications
PIPELINE OF ADDITIONAL INDICATIONS TRAUMATIC BRAIN ALZHEIMER’S HYPOXIC-ISCHAEMIC INJURY DISEASE ENCEPHALOPATHY (HIE) ARGENICA THERAPEUTICS Estimated USD$18.6bn Alzheimer’s therapeutics HIE occurs in 1.5 to 2.5 market size by 20311 market USD$13bn by 20314 births per 10007 Preclinical data shows ARG-
Slide 16: Credentialled & Experienced Team
CREDENTIALLED & EXPERIENCED TEAM GEOFF POCOCK DR LIZ DALLIMORE NON-EXECUTIVE CHAIRMAN CEO • 20 years’ experience in commercialisation of • Over 20 years' experience in R&D, technology commercialisation emerging technologies and capital markets and management consulting, including at KPMG, EY and PWC
Slide 17: Investment Highlights
INVESTMENT HIGHLIGHTS EXPERIENCED WORKING WITH PHASE 2 ETHICS BIOTECH TEAM WORLD LEADING SUBMITTED EXPERTS ARGENICA THERAPEUTICS OPPORTUNITY IN MULTIPLE ACCESSED TARGETING LARGE APPLICATIONS NON-DILUTIVE ADDRESSABLE & PIPELINE FUNDING MARKETS 17 www.argenica.com.au
Slide 18: Argenica Therapeutics
ARGENICA THERAPEUTICS For further information please contact: Dr Liz Dallimore CEO & Managing Director E: info@argenica.com.au 18 www.argenica.com.au
Argenica Therapeutics — Investor Presentation (July 2023) on 6ix